Women who develop diabetes during pregnancy, called gestational diabetes, perform worse on cognitive function tests than do women with a normal pregnancy, according to a new study from Turkey. The results were presented Sunday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
Long-term mild cold exposure can stimulate brown fat growth and activity in humans and may benefit glucose and energy metabolism, a new study finds. The results were presented in a poster Sunday, June 22 at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago.
ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, has tallied more registrants than any other annual meeting in the Endocrine Society’s nearly 100-year history.
Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of fractures, and a favorable benefit/risk profile, a new multinational study finds. The results were presented Sunday, June 22, at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago.
A new study has found for the first time that the endocrine-disrupting chemical bisphenol A (BPA) reprograms the developing prostate, making the gland more susceptible to precancerous lesions and other diseases later in a man’s life. The results will be reported Sunday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
People with significant hypothyroidism can experience impaired driving similar to those who are driving when intoxicated by alcohol, a new study finds. The results were presented Sunday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
Researchers have found a possible biological reason why people with diabetes are prone to depression. A new study shows that high blood glucose (sugar) levels in patients with Type 1 diabetes increase the levels of a brain neurotransmitter associated with depression, and alter the connections between regions of the brain that control emotions. The results will be presented Sunday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
Soy protein supplements, which contain natural estrogens, do not reduce testosterone levels in men with Type 2 diabetes who already have borderline-low testosterone, according to a new study. The results were presented Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
Almost 70 percent of adults with Type 1 diabetes never use their blood glucose self-monitoring devices or insulin pumps to download historical data about their blood sugar levels and insulin doses—information that likely would help them manage their disease better. These new survey results, which were presented Sunday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago, also show that only 12 percent of patients regularly review their past glucose and insulin pump data at home.
Growth Hormone Defect May Protect against Diabetes, Cancer in Unique Ecuador Population
A study finds that the number of taste buds we have on our tongue decreases as we get older, and that the lower the number of taste buds, the more likely for fasting blood glucose (sugar) levels to be higher than normal. The results will be presented Sunday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
Vitamin D treatment acts in the brain to improve weight and blood glucose (sugar) control in obese rats, according to a new study being presented Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
In soldiers who survive traumatic brain injury from blast exposure, pituitary dysfunction after their blast injury may be an important, under-recognized, and potentially treatable source of their symptoms, a new study finds. The results were presented Saturday, June 21 at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago.
Women with polycystic ovary syndrome are at increased risk for type 2 diabetes mellitus (T2DM), and this risk appears to be independent of body mass index (BMI), a new study finds. The results were presented Saturday at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago.
Researchers believe they have discovered one reason why some women with estrogen receptor-positive breast cancer may respond poorly or only temporarily to estrogen-blocking drugs such as tamoxifen. Results of a new study, which was presented Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago, point to a previously unrecognized role of the androgen receptor.
Nondiabetic obese and overweight people lose more weight, are more likely to reverse prediabetes and are slower to develop type 2 diabetes when they take the diabetes drug liraglutide in addition to dieting and exercising, a new study finds. The results of the multicenter study were presented Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
Vitamin D and calcium supplementation along with diet and exercise may prevent Type 2 diabetes in prediabetic individuals who have insufficient vitamin D in their bodies, a study from India suggests. The results were presented Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
Women with Type 2 diabetes and high cholesterol are less likely than their male peers to reach treatment goals to lower their “bad” cholesterol, or low-density lipoprotein (LDL) cholesterol, despite access to cholesterol-lowering medication, a Canadian study finds. The results were presented on Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
Obese pregnant women who adhere to an intensive nutritional and exercise program starting in the first trimester gain less weight in pregnancy and have fewer pregnancy complications compared with peers who receive standard prenatal care, a new study from China finds. The results were presented Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
Adult offspring of mothers who used fluoxetine, a common antidepressant, during pregnancy were more likely to develop a fatty liver, a new animal study has found. The results will be reported Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.
Measuring pregnant women's blood kisspeptin levels early in their pregnancy may effectively predict their risk of miscarriage, a new study finds. The results will be presented Saturday at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago.
Researchers have demonstrated for the first time in an animal model that maternal use of a class of antidepressants called selective serotonin reuptake inhibitors, or SSRIs, resulted in increased fat accumulation and inflammation in the liver of the adult offspring, raising new concerns about the long-term metabolic complications in children born to women who take SSRI antidepressants during pregnancy.
Researchers at the University of Montreal and CHUM Research Centre (CRCHUM) recently demonstrated the potential of retinoic acid (RA), a derivative of Vitamin A, in treating obesity and type 2 diabetes and preventing their cardiovascular complications.
Researchers from the University of Virginia Center for Diabetes Technology are presenting their findings from artificial pancreas clinical trials at the American Diabetes Association’s 74th Scientific Sessions in San Francisco on June 14-15.
The latest research discoveries on diabetes, weight loss, endocrine-disrupting chemicals, obesity and pregnancy hormones will be highlighted in a series of press conferences at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society.
Rheumatoid arthritis patients overall are twice as likely as the average person to develop heart problems. Pinpointing which rheumatoid arthritis patients need stepped-up heart disease prevention efforts has been a challenge; research by Mayo Clinic and others has found that standard heart disease risk assessment tools may underrate the danger a particular person faces. To better pinpoint rheumatoid arthritis patients’ heart disease risk, an international team that includes Mayo researchers has created a heart disease risk calculator tailored to rheumatoid arthritis.
There are substantial differences between the results provided by Agendia’s breast cancer genomic tests and more limited results from the 21-gene assay, according to findings presented at the recently concluded ASCO meeting.
Einstein-Montefiore scientists and clinicians are participating in nearly three dozen presentations, sessions and symposia during the five-day meeting. They will address a range of basic, translational and clinical research topics—from medication adherence in adolescents and the impact on resveratrol and vitamin D on insulin resistance to epigenetic and genetic triggers for the disease.
A research study led by cancer specialists at MedStar Washington Hospital Center found that African-American women frequently present with biologically less favorable subtypes of breast cancer.
Loyola University Medical Center achieved a 68 percent decrease in the overall number of central line-associated bloodstream infections (CLABSI) over a 12-month period. A two-year study compared the use of disinfection caps to an intense scrub-the-hub intervention to standard care. Scrub-the-hub refers to cleaning catheter connector hubs and injection ports with alcohol for the recommended 15 seconds before accessing the central line, a catheter placed in a large vein to deliver medicine and liquids during hospitalization.
Dartmouth researchers have found that those caring for patients with advanced cancer experienced reduced depression and felt less burdened by caregiving tasks when palliative support services were offered soon after the patient’s diagnosis. They presented their findings at the American Society of Clinical Oncologist (ASCO) annual meeting in Chicago on June 3, 2014.
While countless pet owners peacefully sleep with a warm pet nearby, a new Mayo Clinic study, presented this week at the 29th Annual Meeting of the Associated Professional Sleep Societies, finds an increase in the number of people experiencing sleep disturbances because of their pets.
UAB School of Nursing federally funded study shows both the patient and caregiver benefit from early palliative care.
Results presented today at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) and June 6 at the European Association of Palliative Care Research Conference show that stopping statins for cholesterol management in the late stages of cancer or other terminal illnesses may offer quality-of-life and even life-extending benefits.
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
Teenage girls with a familial or genetic risk for breast cancer worry more about getting the disease, even when their mother has no history, compared to girls their age with no known high risks, according to new data presented today by researchers from Penn Medicine’s Abramson Cancer Center at the annual meeting of the American Society of Clinical Oncology in Chicago.
CHICAGO – New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). These treatments – used alone or in combination – fight cancer by activating and amplifying the body’s immune response to the disease.
Research presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2014 used a newly designed test for K:B fusion to show that point mutations lead to a more dangerous form of the disease than does K:B fusion.
Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were presented today at the 2014 American Society of Clinical Oncology Annual Meeting.
Findings from four phase III clinical trials in breast, prostate, and colorectal cancers were released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies were presented in ASCO’s Plenary session, which features the meeting’s most important clinical cancer research with the greatest potential to impact patient care.
CHICAGO — A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone. The findings were part of the results of a Phase III clinical trial presented today at the 2014 American Society of Clinical Oncology Annual Meeting by the study’s primary author Jan Buckner, M.D., deputy director, Cancer Practice, at Mayo Clinic Cancer Center.
CHICAGO — June 2, 2014 — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th annual meeting of the American Society of Clinical Oncology (ASCO).
Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group.
Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago.
At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs).
Key studies released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) identify new strategies for easing the short- and long-term effects of cancer therapy and improving the quality of life of patients with cancer, as well as their caregivers.
A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation.
A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.
Cancer panel reveals new insights in HPV cancers.
Among young breast cancer patients, one of the most distressing side effects of chemotherapy is early menopause. But a major study finds the risk of early menopause can be significantly reduced by adding the drug goserelin to the chemotherapy regimen.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right